Literature DB >> 32608109

Lupus anticoagulant is frequent in patients with Covid-19: Response to Reply.

Inès Harzallah1, Agathe Debliquis1, Bernard Drénou1.   

Abstract

We have recently published in the Journal of Thrombosis and Haemostasis the presence of lupus anticoagulant (LAC) at high frequency in Covid-19 patients (1). Different authors had confirmed these results (2). Connell and colleagues had discussed, in the Journal, technical points concerning LAC as well as anti-phospholipids (aPL) auto-antibodies detection (3). This article is protected by copyright. All rights reserved.

Entities:  

Year:  2020        PMID： 32608109      PMCID： PMC7361771          DOI： 10.1111/jth.14980

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN： 1538-7836            Impact factor:   5.824


  14 in total

Review 1.  Antiphospholipid syndrome: Complement activation, complement gene mutations, and therapeutic implications.

Authors:  Shruti Chaturvedi; Evan M Braunstein; Robert A Brodsky
Journal:  J Thromb Haemost       Date:  2021-02-10       Impact factor: 5.824

2.  Evaluation of Antiphospholipid Antibodies in COVID-19 Patients with Coagulopathy.

Authors:  Anahita Nosrati; Zhila Torabizadeh; Donya Kheirkhah; Lale Vahedi Larijani; Reza Alizade-Navaei; Maryam Mobini; Masoud Aliyali; Siavash Abedi; Hossein Mehravaran
Journal:  Tanaffos       Date:  2022-01

3.  Incidence of lupus anticoagulant in hospitalized covid-19 patients.

Authors:  Tarek Owaidah; Mahasen Saleh; Amelita M Aguilos; Abdulllah Al Amri; Khalid Maghrabi; Mustafa Owaidah; Khawar Siddiqui; Khalid Alsaleh; Randa Alnounou
Journal:  Am J Blood Res       Date:  2021-06-15

4.  Pattern of anticoagulation prescription for patients with Covid-19 acute respiratory distress syndrome admitted to ICU. Does it impact outcome?

Authors:  Rashid Nadeem; Stelvie John Thomas; Zoubia Fathima; Anju Subin Palathinkal; Yazan Emad Alkilani; Efaf Ahmad Dejan; Ismail Mohammad Ismail Darwish; Aisha Ali Alsubousi; Allaa Marouf Backour; Hussein Kandeel; Mohamad Omar; Hesham Fawzy Yehia Taha Kewan; Mahmod Elshahat Makhlof; Anand Bhaskarrao Kotgire
Journal:  Heart Lung       Date:  2020-10-20       Impact factor: 2.210

Review 5.  Induced dysregulation of ACE2 by SARS-CoV-2 plays a key role in COVID-19 severity.

Authors:  Maryam Eskandari Mehrabadi; Roohullah Hemmati; Amin Tashakor; Ahmad Homaei; Masoumeh Yousefzadeh; Karim Hemati; Saman Hosseinkhani
Journal:  Biomed Pharmacother       Date:  2021-02-05       Impact factor: 7.419

Review 6.  Pathophysiological Processes Underlying the High Prevalence of Deep Vein Thrombosis in Critically Ill COVID-19 Patients.

Authors:  Sebastian Voicu; Chahinez Ketfi; Alain Stépanian; Benjamin G Chousterman; Nassim Mohamedi; Virginie Siguret; Alexandre Mebazaa; Bruno Mégarbane; Philippe Bonnin
Journal:  Front Physiol       Date:  2021-01-08       Impact factor: 4.566

7.  Lupus anticoagulant and mortality in patients hospitalized for COVID-19.

Authors:  Carmine Gazzaruso; Giuseppe Mariani; Carolina Ravetto; Laura Malinverni; Elena Tondelli; Maria Cerrone; Vittorio Sala; Luigi Bevilacqua; Teodoro Altavilla; Adriana Coppola; Pietro Gallotti
Journal:  J Thromb Thrombolysis       Date:  2020-11-07       Impact factor: 2.300

Review 8.  Hematologic parameters in coronavirus infection (COVID-19) and their clinical implications.

Authors:  Rao Muhammad Waleed; Inbisat Sehar; Waleed Iftikhar; Huma Saeed Khan
Journal:  Discoveries (Craiova)       Date:  2020-10-01

Review 9.  The Interplay Between Coagulation and Inflammation Pathways in COVID-19-Associated Respiratory Failure: A Narrative Review.

Authors:  Rajat Bhattacharyya; Prasad Iyer; Ghee Chee Phua; Jan Hau Lee
Journal:  Pulm Ther       Date:  2020-08-25

Review 10.  Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications.

Authors:  Joan T Merrill; Doruk Erkan; Jerald Winakur; Judith A James
Journal:  Nat Rev Rheumatol       Date:  2020-07-30       Impact factor: 20.543
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.